Fineline Cube

Follow:
14422 Articles
CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials
CompanyDrug

CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials

Genrix Succeeds with Telikibart Phase 3, Targets Atopic Dermatitis
CompanyDrug

Genrix Succeeds with Telikibart Phase 3, Targets Atopic Dermatitis

HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor
CompanyDeals

HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor

Lion TCR Secures FDA Approval for LioCyx‑M004, Launching Phase Ib/II Trial in Chronic Hepatitis B
Drug

Lion TCR Secures FDA Approval for LioCyx‑M004, Launching Phase Ib/II Trial in Chronic Hepatitis B

Biokin Pharma Secures Breakthrough Therapy Designation for izalontamab with BMS
CompanyDrug

Biokin Pharma Secures Breakthrough Therapy Designation for izalontamab with BMS

Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal
CompanyDeals

Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal

Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033
CompanyDeals

Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033

BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth
CompanyDeals

BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth

NMPA Releases 96th Reference Listed Drugs Catalog, Adding 42 New Generic Specifications
Policy / Regulatory

NMPA Releases 96th Reference Listed Drugs Catalog, Adding 42 New Generic Specifications

CSPC Pharmaceutical Group Submits Anbenitamab for NMPA Approval in HER2‑Positive Gastric Cancer
CompanyDrug

CSPC Pharmaceutical Group Submits Anbenitamab for NMPA Approval in HER2‑Positive Gastric Cancer

BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC
CompanyDrug

BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC

Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference
CompanyDrug

Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference